These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 22024013)
1. A review of the economic evaluation of interventions for cardiovascular diseases in Spain. Catalá-López F; García-Altés A; Alvarez-Martín E; Gènova-Maleras R; Morant-Ginestar C; Fernández de Larrea-Baz N Farm Hosp; 2012; 36(3):163-5. PubMed ID: 22024013 [No Abstract] [Full Text] [Related]
2. Economic evaluation of interventions for malignant neoplasms in Spain: systematic review and comparative analysis. Catalá-López F; García-Altés A; Álvarez-Martín E; Gènova-Maleras R; Morant-Ginestar C; Arana E Farm Hosp; 2012; 36(3):141-7. PubMed ID: 22030159 [TBL] [Abstract][Full Text] [Related]
3. Bayesian estimation of cost-effectiveness from censored data. Heitjan DF; Kim CY; Li H Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484 [TBL] [Abstract][Full Text] [Related]
4. Clinical and economical outcome of a cardiopulmonary and metabolic rehabilitation program. Di Naso FC; Pereira JS; Monteiro MB Arq Bras Cardiol; 2007 Oct; 89(4):274; author reply 274-5. PubMed ID: 17992386 [No Abstract] [Full Text] [Related]
6. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data. Vázquez-Polo FJ; Negrín Hernández MA; López-Valcárcel BG Health Econ; 2005 Jun; 14(6):545-57. PubMed ID: 15497202 [TBL] [Abstract][Full Text] [Related]
7. Economic benefits of secondary and tertiary cardiac rehabilitation: a critical study. Shephard RJ Ann Acad Med Singap; 1992 Jan; 21(1):57-62. PubMed ID: 1590659 [TBL] [Abstract][Full Text] [Related]
8. Power and sample size calculations for stochastic cost-effectiveness analysis. Briggs AH; Gray AM Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469 [TBL] [Abstract][Full Text] [Related]
9. Numbers needed to treat (lives!) and numbers needed to save (money). Ribichini F; Taggart D; Vassanelli C EuroIntervention; 2013 Jun; 9(2):175-7. PubMed ID: 23793004 [No Abstract] [Full Text] [Related]
10. [Admission criteria for cardiac rehabilitation]. Greco C; Bianchi M; Rasile C G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 3):121S-123S. PubMed ID: 20879497 [No Abstract] [Full Text] [Related]
11. Lifestyle modification interventions and cardiovascular health: global perspectives on worksite health and wellness and cardiac rehabilitation. Arena R Prog Cardiovasc Dis; 2014; 56(5):473-5. PubMed ID: 24607010 [No Abstract] [Full Text] [Related]
12. Difficulties in analyzing costs and benefits in outpatient cardiac rehabilitation programs. Hepner N; Hayes SM NLN Publ; 1987 Dec; (20-2191):421-31. PubMed ID: 3122171 [No Abstract] [Full Text] [Related]
13. Principles from clinical trials relevant to clinical practice: Part II. Califf RM; DeMets DL Circulation; 2002 Aug; 106(9):1172-5. PubMed ID: 12196347 [No Abstract] [Full Text] [Related]
14. [Economic effectiveness of prophylactic and therapeutic measures in cardiovascular diseases]. Roĭtman MP; Lunskaia LL Sov Zdravookhr; 1982; (5):50-4. PubMed ID: 6808669 [No Abstract] [Full Text] [Related]
15. A study on confidence intervals for incremental cost-effectiveness ratios. Wang H; Zhao H Biom J; 2008 Aug; 50(4):505-14. PubMed ID: 18663759 [TBL] [Abstract][Full Text] [Related]
16. Identifying favorable-value cardiovascular health services. Braithwaite RS; Mentor SM Am J Manag Care; 2011 Jun; 17(6):431-8. PubMed ID: 21756013 [TBL] [Abstract][Full Text] [Related]